Key result
In stable HeartMate 3 LVAD recipients, sacubitril/valsartan did not reduce the primary composite endpoint compared to standard of care.
Why the study?
Does sacubitril/valsartan improve safety and tolerability compared to standard of care in stable HeartMate 3 LVAD recipients?
RCT (n=60)
Open-label
randomized
Yes
Does sacubitril/valsartan improve safety and tolerability compared to standard of care in stable HeartMate 3 LVAD recipients?
Answers are grounded in this paper and cite their sources.
In stable HeartMate 3 LVAD recipients, sacubitril/valsartan was safe and well-tolerated for blood pressure management, with trends toward reduced BP medication burden and improved quality of life.
The role of heart failure specific therapies in LVAD recipients is unclear and observational data suggest improved outcomes with neurohormonal blockers. ENVAD-HF evaluated safety and tolerability of the Angiotensin-Neprilysin Inhibitor sacubitril/valsartan, for managing blood pressure (BP) in HeartMate 3 (HM3) LVAD recipients versus standard of care (SOC). ENVAD-HF was a prospective multicenter, randomized, open-label study of sacubitril/valsartan or SOC for managing BP (MAP goal 75-90 mmHg) in stable LVAD recipients with 12-month follow-up. The composite primary endpoint was time to death, deterioration in renal function, hyperkalemia or symptomatic hypotension leading to drug withdrawal. Exploratory endpoints included clinical and biomarker assessments and patient-reported outcomes. Among 60 randomized patients (30 in each arm), sacubitril/valsartan compared to SOC demonstrated a HR of 0.42, 95% CI 0.08-2.18; p=0.30 for the primary endpoint at 12 months. Two primary endpoints were reached in the sacubitril/valsartan group (one death and one symptomatic hypotension) compared with five in the SOC group (two deaths, two worsening renal function events and one symptomatic hypotension). Numerical trends in favor of sacubitril/valsartan were noted for other exploratory endpoints, including reduced number of BP medications (difference: -1.09; 95% CI -1.52 to -0.66, p <0.0001) and significantly better KCCQ OSS (improvement: +10.6, 95% CI 2.6 to 18.7, p=0.011). ENVAD-HF, a prospective randomized controlled trial of Angiotensin-Neprilysin Inhibition in stable HM3 LVAD recipients demonstrated safety and tolerability of this therapy in this unique population. The trial forms the basis for a pivotal trial to investigate the usefulness of HF-specific therapies in the LVAD population. Clinicaltrials.gov: NCT04103554 and EudraCT: 2019-003888-22.
No takes yet. Share an insight, caveat, or question.
Čikeš et al. (2025) conducted an RCT in Heart failure with HeartMate 3 LVAD (n=60). sacubitril/valsartan vs. standard of care (SOC) was evaluated on time to death, deterioration in renal function, hyperkalemia or symptomatic hypotension leading to drug withdrawal (HR 0.42, 95% CI 0.08-2.18, p=0.30). In stable HeartMate 3 LVAD recipients, sacubitril/valsartan did not reduce the primary composite endpoint compared to standard of care.
Synapse has enriched 10 related papers. Consider them for comparative context: